Binding of cordycepin monophosphate to amp-activated protein kinase and its effect on amp-activated protein kinase activation

Chemical Biology and Drug Design

Volumn 76, Issue 4, 2010, Pages 340-344

  Wang, Zhanli ^a   Wang, Xing ^b   Qu, Kai ^b   Zhu, Ping ^b   Guo, Na ^b   Zhang, Ruiping ^b   Abliz, Zeper ^b   Yu, Hui ^c   Zhu, Haibo ^b  

^a ZHEJIANG UNIVERSITY OF TECHNOLOGY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

adenosine monophosphate (AMP); AMP activated protein kinase; cordycepin; cordycepin monophosphate; molecular docking

Indexed keywords

CORDYCEPIN; CORDYCEPIN MONOPHOSPHATE; DRUG METABOLITE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CRYSTALLOGRAPHY; DRUG STRUCTURE; ENZYME ACTIVATION; HYDROGEN BOND; MOLECULAR DOCKING; PRIORITY JOURNAL;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; BINDING SITES; COMPUTER SIMULATION; DEOXYADENOSINES; HYDROGEN BONDING; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY;

EID: 77956413328     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2010.01019.x     Document Type: Article

References (19)

1. Kahn B.B., Alquier T., Carling D., Hardie D.G. (2005) AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab 1 : 15 25.
2. Xiao B., Heath R., Saiu P., Leiper F.C., Leone P., Jing C., Walker P.A., Haire L., Eccleston J.F., Davis C.T. (2007) Structural basis for AMP binding to mammalian AMP-activated protein kinase. Nature 449 : 496 500.
3. Hardie D.G., Hawley S.A. (2001) AMP-activated protein kinase: the energy charge hypothesis revisited. Bioessays 23 : 1112 1119.
4. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., Dickinson R. et al. (2006) Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab 3 : 403 416.
5. Yamanaka G., Wilson T., Innaimo S., Bisacchi G.S., Egli P., Rinehart J.K., Zahler R., Colonno R.J. (1999) Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus. Antimicrob Agents Chemother 43 : 190 193.
6. Gruber H.E. US Patent 5,658,889, August 19, 1997.
7. Mueller W.E.G., Weiler B.E., Charubala R., Pfleiderer W., Leserman L., Sobol R.W., Suhadolnik R.J., Schroeder H.C. (1991) Cordycepin analogues of oligoadenylate inhibit human immunodeficiency virus infection via inhibition of reverse transcriptase. Biochem Wash 30 : 2027 2033.
8. Sugar A.M., McCaffrey R.P. (1998) Antifungal activity of 3′-deoxyadenosine (cordycepin). Antimicrob Agents Chemother 42 : 1424 1427.
9. Okoshi R., Ozaki T., Yamamoto H., Ando K., Koida N., Ono S., Koda T., Kamijo T., Nakagawara A., Kizaki H. (2008) Activation of AMP-activated protein kinase induces p53-dependent apoptotic cell death in response to energetic stress. J Biol Chem 283 : 3979 3987.
10. Wong Y.Y., Moon A., Duffin R., Barthet-Barateig A., Meijer H.A., Clemens M.J., de Moor C.H. (2010) Cordycepin inhibits protein synthesis and cell adhesion through effects on signal transduction. J Biol Chem 285 : 2610 2621.
11. Morris G.M., Goodshell D.S., Halliday R.S., Huey R., Hart W.E., Belew R.K., Olson A.J. (1998) Automated docking using a Lamarckian genetic algorithm and empirical binding free energy function. J Comput Chem 19 : 1639 1662.
12. Townley R., Shapiro L. (2007) Crystal structures of the adenylate sensor from fission yeast AMP-activated protein kinase. Science 315 : 1726 1729.
13. Zsoldos Z., Reid D., Simon A., Sadjad B.S., Johnson A.P. (2006) eHiTS: an innovative approach to the docking and scoring function problems. Curr Protein Pept Sci 7 : 421 435.
14. Ko H.J., Zhang Z., Jung D.Y., Jun J.Y., Ma Z., Jones K.E., Chan S.Y., Kim J.K. (2009) Nutrient stress activates inflammation and reduces glucose metabolism by suppressing AMP-activated protein kinase in the heart. Diabetes 58 : 2536 2546.
15. Gruzman A., Babai G., Sasson S. (2009) Adenosine monophosphate-activated protein kinase (AMPK) as a new target for antidiabetic drugs: a review on metabolic, pharmacological and chemical considerations. Rev Diabet Stud 6 : 13 36.
16. Guo D., Hildebrandt I.J., Prins R.M., Soto H., Mazzotta M.M., Dang J., Czernin J., Shyy J.Y., Watson A.D., Phelps M., Radu C.G., Cloughesy T.F., Mischel P.S. (2009) The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A 106 : 12932 12937.
17. Erion M.D., Dang Q., Reddy M.R., Kasibhatla S.R., Huang J., Lipscomb W.N., van Poelje P.D. (2007) Structure-guided design of AMP mimics that inhibit fructose-1, 6- bisphosphatase with high affinity and specificity. J Am Chem Soc 129 : 15480 15490.
18. Reddy M.R., Erion M.D. (2001) Calculation of relative binding free energy differences for fructose 1, 6-bisphosphatase inhibitors using the thermodynamic cycle perturbation approach. J Am Chem Soc 123 : 6246 6252.
19. Reddy M.R., Erion M.D. (2007) Relative binding affinities of fructose-1,6- bisphosphatase inhibitors calculated using a quantum mechanics-based free energy perturbation method. J Am Chem Soc 129 : 9296 9297.